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Abstract
Background: The growth factor progranulin has been implicated in numerous biological processes such as wound
healing, inflammation and progressive tumorigenesis. Both progranulin and its receptor sortilin are known to be
highly expressed in subgroups of breast cancer and have been associated with various clinical properties including
tamoxifen resistance. Recent data further suggest that progranulin, via its receptor sortilin, drives breast cancer stem
cell propagation in vitro and increases metastasis formation in an in vivo breast cancer xenograft model. In this
retrospective biomarker analysis, we aimed to determine whether tumor co-expression of progranulin and sortilin
has prognostic and treatment predictive values for breast cancer patients.
Methods: We explored how co-expression of progranulin and sortilin was associated with established clinical
markers by analyzing a tissue microarray including 560 randomized premenopausal breast cancer patients receiving
either 2 years of tamoxifen treatment or no adjuvant treatment, with a median follow-up time of 28 years. Breast
cancer-specific survival was analyzed using Kaplan-Meier and Cox Proportional Hazards regression models to assess
the prognostic and predictive value of progranulin and sortilin in relation to known clinical markers.
Results: Co-expression of progranulin and sortilin was observed in 20% of the breast cancer samples. In untreated
patients, prognostic considerations could be detailed separately from treatment prediction and the high
progranulin and sortilin expressing subgroup was significantly associated with breast cancer-specific death in
multivariable analyses (HR=2.188, CI: 1.317–3.637, p=0.003) along with tumor size, high tumor grade and lymph
node positivity. When comparing the untreated patients with tamoxifen treated patients in the ERα positive
subgroup, co-expression of progranulin and sortilin was not linked to tamoxifen resistance.
Conclusion: Data suggest that co-expression of progranulin and its receptor sortilin is a novel prognostic
biomarker combination identifying a highly malignant subgroup of breast cancer. Importantly, this subpopulation
could potentially be targeted with anti-sortilin based therapies.
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Background
Breast cancer is the most common cancer in women
worldwide. Even though early detection rates and exist-
ing therapies contribute to a slightly enhanced survival,
many patients experience metastasis and tumor relapse.
As a result, breast cancer remains the leading cause of
cancer death among the female population [1]. Treat-
ment failure and cancer recurrence are multifactorial
but most likely influenced by drug resistance and self-
renewal properties of the small population of tumor cells
termed cancer stem cells (CSCs) [2]. Further, breast can-
cer is in many aspects a heterogeneous disease, including
subtypes with diverse phenotypes and clinical behaviors
[3–5]. Each subtype is responsive to different treatment
regimes. Patients that express the estrogen receptor
alpha (ERα) are treated with endocrine adjuvant therapy,
such as tamoxifen or an aromatase inhibitor. However,
despite that endocrine therapy improves the survival of
the ERα positive patient group, many patients experience
tumor relapse or therapy resistance [6]. Consequently,
there is an obvious need to further identify key media-
tors involved in breast cancer progression in order to
optimally distinguish subgroups of breast cancer patients
that will benefit from specific treatments or having tu-
mors with inherent aggressive properties.
The pleiotropic growth factor progranulin has been
identified as a key mediator involved in breast cancer
progression and is further influenced by the tumor
microenvironment, which can lead to breast CSC propa-
gation and drug resistance [7–12]. We recently observed
that progranulin secretion is induced in ERα positive
breast cancer cells exposed to a hypoxic environment,
which further induced breast CSC propagation [7]. In
fact, progranulin present in serum has been demon-
strated to predict recurrence in hormone positive (ERα
and progesterone receptor (PR) positive) breast cancer
patients during tamoxifen treatment [13]. In addition,
high levels of progranulin expression in tumors from pa-
tients with ERα positive invasive ductal carcinoma (IDC)
is associated with increased risk of recurrence [14]. Fur-
ther, Li and colleagues demonstrated that progranulin
tumor expression was significantly higher in tumors
from triple negative breast cancer patients without pres-
ence of lymph node metastasis [15]. These triple nega-
tive breast tumors also expressed high levels of vascular
endothelial growth factor and cluster of differentiation
105 (Endoglin) and high progranulin expression further
correlated with epidermal growth factor receptor, sug-
gesting that progranulin is involved in the high angio-
genesis in this specific subset of breast cancer.
In addition, progranulin is involved in various bio-
logical processes, such as wound healing, tumorigenesis,
inflammation and has been associated with various
neurological diseases [16–23]. The fact that high
progranulin has been observed in both tissue and serum
of various cancer types compared to normal tissue [9,
12, 13, 24–30] suggests that progranulin may be a rele-
vant biomarker in breast cancer, as well as in other can-
cer types [13, 14].
Moreover, sortilin is a known progranulin binding re-
ceptor [31], highly expressed in breast cancer cell lines
compared to non-tumorigenic breast epithelial cells [32].
Sortilin has also been associated with increased meta-
static potential in both IDC and invasive lobular carcin-
oma (ILC) [32], suggesting that the progranulin receptor
could also be involved in breast cancer progression.
In this study, we investigated tumor specific expression
and potential clinical associations for progranulin and its
associated receptor sortilin, with the aim to identify opti-
mal biomarkers for breast cancer progression and prog-
nosis that could potentially be targeted by anti-sortilin
based therapy. This study was performed according to
the REMARK guidelines (presented in Additional file 1)
using tissue microarrays (TMAs) from a randomized




The original study (SBII:2) was approved by the Ethics
Committee at Lund and Linköping Universities, Sweden
(Dnr LU 240–01 and for the continuation of the study:
Dnr Linköping 01–134 and Dnr LU 2015–350).
Randomization was performed by the Regional Onco-
logical Centers and oral informed consent was registered
for all patients. The data were analyzed anonymously.
Patients and tumor samples
This retrospective study includes an invasive breast can-
cer cohort consisting of 560 premenopausal patients en-
rolled in a randomized clinical trial from 1984 to 1991,
where patients received either 2 years of tamoxifen treat-
ment (n=275) or no systemic treatment (randomized un-
treated) (n=285). Each patient underwent surgery (either
radical mastectomy or breast-conserving surgery)
followed by radiotherapy, and in a small number of cases
adjuvant polychemotherapy (> 2%). All patients were
followed-up for breast cancer-specific survival (BCSS)
with up to 32 years of follow-up data. BCSS was calcu-
lated as the time from surgery of the primary breast
tumor to death from breast cancer. The median post-
surgery follow-up time without a breast cancer-specific
death was 28.41 years. ERα status was determined by im-
munohistochemistry or enzyme immunoassay, proges-
terone receptor (PR) status by immunohistochemistry
and human epidermal growth factor receptor 2 (HER2)
status was determined by in situ hybridization and im-
munohistochemistry, as previously described and with a
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cut-off value of 10% to assess the hormone status of
ERα, PR and HER2 [33, 34]. Among the 444 patients an-
alyzed for progranulin and sortilin expression, 317 were
considered ERα positive and 96 patients were ERα nega-
tive; 230 patients were PR positive, whereas 124 were
negative for PR. For HER2 status, 358 patients were
HER2 negative and 60 patients HER2 positive. A CON-
SORT diagram for the trial profile is given in Add-
itional file 5: Fig. S1 and clinical and tumor
characteristics for the two study groups are presented in
Table 1. Additional details of the trial have been de-
scribed previously [33, 35, 36].
Antibodies and immunohistochemistry
Representative tumor areas of formalin-fixed and paraffin-
embedded tissue material were collected from 444 of the
560 patients and selected for TMA construction and sec-
tioned, followed by deparaffinization and rehydration as
previously described [35]. Progranulin and sortilin expres-
sion were determined by immunohistochemistry using an
Autostainer LINK 48 and the Envision FLEX+ detection
system (DAKO). Deparaffinized sections (4.5 μm) were
subjected to antigen retrieval by high pressure cocking
and DIVA antigen retrieval pH 6.2, followed by blocking
with 3% hydrogen peroxide and incubation with primary
antibody against progranulin (polyclonal goat anti-
Progranulin, #AF2420, R&D Systems 1:1000) and sortilin
(polyclonal rabbit anti-Sortilin, #AB16640, ABCAM 1:
1000) at room temperature for 1 h. For signal amplifica-
tion of the primary rabbit anti-Sortilin antibody, EnVi-
sion™ FLEX+ Rabbit linker (SM805, DAKO) was used. A
secondary antibody (polyclonal rabbit anti-goat immuno-
globulins/HRP, #P0449, DAKO 1:100) was used for the
progranulin staining, followed by signal amplification
using EnVision™ FLEX+ Rabbit linker (SM805, DAKO).
Further, the EnVision FLEX/HRP visualization reagent
EnVision™ FLEX/HRP secondary antibody-coated polymer
peroxidase complexes (#SM802, DAKO) was used,
followed by DAB substrate/chromogen (DAKO). Slides
were counterstained with hematoxylin (DAKO) and
stained sections were scanned by a Leica SCN400 scanner
at 20X. Antibody validation for IHC assessment of sortilin
and progranulin has been performed previously by siRNA
knockdown, protease degradation and western blot ana-
lysis [31, 37–39]. Additionally, antibody validation has
been performed in this study, using IHC and western blot
analysis, including siRNA knockdown and chemical deg-
radation on established breast cancer cell lines (see Add-
itional files 2, 3, 4).
Scoring
Evaluation and scoring of progranulin and sortilin tumor
expression were performed independently by a patholo-
gists (Landberg) and a trained breast cancer surgeon
(Rafnsdóttir) without knowledge of pathological or clin-
ical data. The scoring system was implemented using an
Allred scoring system, ranging from 1 (no/low staining),
2 (low/intermediate staining), 3 (intermediate/high stain-
ing) to 4 (high staining). Expression of progranulin and
sortilin was evaluated in cancer cells only. There was a
similar expression profile between the replicates of the
same tumor throughout the cohort. For progranulin,
78% of the scores were based on two replicates and 22%
of one replicate with no variation between replicates. For
sortilin, 76% of the scores were based on two replicates
and 24% of one replicate. Here, 85% of the total repli-
cates were similar. In high and low, 93% were similar.
For both sortilin and progranulin there were a diver-
gence in the independent scoring judgement of 12%,
however, only 0–2% affected the grouping high/low.
Statistical analysis
All statistical calculations and modelling were performed
in SPSS software version 25 (SPSS, Chicago, IL), Graph-
Pad Prism version 7.00 (GraphPad Software, San Diego,
CA) or RStudio version 3.6.2 (packages stats, ggplot2,
rms, survival and survminer). Spearman’s rank-order
Correlation Coefficient was used to test the significance
of the association between progranulin and sortilin scor-
ing. The relationship between progranulin and sortilin
scoring and various parameters were analyzed using
Pearson’s Chi-square test for categorical variables and
Kruskal-Wallis (or Man-Whitney U) test for continuous
variables. Kaplan-Meier curves were used to estimate
BCSS, and the log-rank test was used to compare BCSS
among different staining scores and treatments, as well
as to calculate Hazard Ratio (HR) and 95% Confidence
Interval (CI) in these groups. Univariate and multivari-
able analysis were performed using Cox proportional
hazard model for relative risk estimation of different var-
iables, including tumor grade, tumor size, age, lymph
node status and ERα status, to compare BCSS among
different treatment groups. For univariate and multivari-
able analysis, HR and 95% CI were calculated. Perform-
ance of the multivariable models were measured using
the concordance index (C-index) and the proportional
hazards assumptions were tested by Schoenfeld resid-
uals. A 10-fold cross-validation, repeated 100 times, was
performed to validate the cohort and estimate the pre-
diction accuracy of the fitted model. All p-values corres-
pond to two-sided tests, and p-values of < 0.05 were
considered statistically significant.
Results
Correlation between progranulin and sortilin expression
and clinicopathological parameters
In order to validate the potential prognostic as well as
treatment predictive value of progranulin and sortilin
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Age at diagnosis (year)
Median 45.00 45.00 45.00
Range 26–57 25–57 25–57
Follow-up time without death from breast cancer
Median 28.09 28.56 28.41
10th percentile 20.48 21.35 20.56
90th percentile 30.85 30.72 30.74
Tumor size (mm)
Median 23.00 25.00 24.00
Range 2–50 8–75 2–75
Tumor histology
Ductal 194 176 370
Lobular 18 17 35
Medullar 13 9 22
Missing: 17
Tumor grade
Grade 1 31 23 54
Grade 2 100 86 186
Grade 3 96 92 188
Missing: 16
Lymph node (LN) status
LN Positive 166 144 310
LN Negative 65 67 132
Missing: 2
Estrogen receptor (ERα)
ERα positive 173 144 317
ERα negative 47 49 96
Missing: 31
Progesterone receptor (PR)
PR positive 122 108 230
PR negative 63 61 124
Missing: 90
Human epidermal growth factor receptor 2 (HER2)
HER2 negative 186 172 358
HER2 positive 35 25 60
Missing: 26
Progranulin expression
High 66 73 139
Low 149 124 273
Missing: 32
Sortilin expression
High 116 109 225
Low 107 95 202
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tumor expression, we analyzed 444 breast cancer
samples arranged in TMAs that were successfully
stained for progranulin and sortilin using immuno-
histochemistry (IHC). Clinicopathological and mo-
lecular parameters included in the study are
summarized in Table 1. The median age of the pa-
tients was 45 years (range 25–57) and the median
follow-up period was 28.41 years. At the last follow-
up, 206 (46.4%) of the 444 patients analyzed had
died of breast cancer. To predict the accuracy of the
multivariable model, a 10-fold cross-validation, re-
peated 100 times, was performed and demonstrated
equivalent results (C-index: 0.642 for all patients in
the full model and mean C-index of the repeated
test-sets: 0.616). For the cohort studied, there was a
significantly increased BCSS for tamoxifen treated
patients having ERα positive cancer (p=0.031, n=384)
(see Additional file 5: Fig. S2).
Breast cancer-specific progranulin and sortilin pro-
tein expression demonstrated very clear staining pat-
terns with cytoplasmic staining without any obvious
membrane staining and total lack of nuclear staining,
as illustrated in Fig. 1. Progranulin and sortilin pro-
tein expression were scored into four groups (illus-
trated in Fig. 1) and further subdivided into low
expression (score 1–2) or high expression (score 3–4).
Among the 444 primary breast tumors selected, 412
tumors were successfully stained for progranulin
where 273 tumors (66.26%) were categorized as
having low progranulin levels (score 1–2) and 139 tu-
mors (33.74%) had high progranulin expression (score
3–4). For sortilin expression analysis, 427 of the 444
breast tumors were successfully stained and 225 tu-
mors had high sortilin expression (score 3–4)
(52.69%) and 202 tumors had low expression of sorti-
lin (47.31%) (score 1–2) (Table 1).
Next, we investigated how progranulin and sortilin
protein expression were associated with established clin-
icopathological parameters. In support for a biological
association, progranulin and sortilin protein expression
correlated significantly (r=0.112, p=0.026) (see Add-
itional file 5: Table S1). Further, progranulin tumor ex-
pression was significantly linked to histological grade
(p< 0.001), where patients with high-grade tumors
showed high progranulin expression, in addition to Ki-
67 (p=0.001) and the hypoxic marker hypoxia-inducible
factor 1-alpha (HIF1α) (p=0.002) (see Additional file 5:
Table S1). There was also a significant association be-
tween progranulin and ERα status (p< 0.001), as well as
PR status (p=0.001) (see Additional file 5: Table S1),
where ERα positive tumors tend to have lower progranu-
lin expression, which is consistent with previous findings
[19]. In addition, sortilin expression was significantly as-
sociated with ERα, where ERα positive tumors tend to
have higher sortilin (p=0.004) and PR expression (p<
0.001). Further, age was also significantly linked to sorti-
lin expression (p=0.040) (see Additional file 5: Table S2).









Fig. 1 Progranulin and sortilin scoring. Representative immunohistochemical images of breast cancer tissue microarray sections showing
variations in progranulin and sortilin expression, scored from 1 to 4, respectively. Brown: positive progranulin/sortilin antibody staining, blue/pale
pink: hematoxylin/eosin for nucleus and cytoplasm staining. Scale bar represents 250 μm
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Patients with high tumor co-expression of progranulin
and sortilin had impaired BCSS
Since the aim of this study was to evaluate the aggres-
siveness of breast cancers expressing both progranulin
and the receptor sortilin, the material was subdivided
into four groups based on progranulin and sortilin co-
expression: 1; low progranulin/low sortilin, 2; low pro-
granulin/high sortilin, 3; high progranulin/low sortilin
and 4; high progranulin/high sortilin (see Additional file
2: Table S3). Out of 395 scored tumors, 79 (20%)
expressed high levels of both progranulin and sortilin,
56 (14.18%) had high progranulin/low sortilin expres-
sion, 129 (32.66%) had high sortilin/low progranulin,
and 131 (33.16%) expressed low levels of both markers.
For the analysis of progranulin and sortilin expression
in relation to BCSS, we initially concentrated on the ran-
domized untreated patients to obtain prognostic infor-
mation not affected by adjuvant tamoxifen treatment (all
univariate data Table 2, left). Interestingly, the double
high progranulin and sortilin group was significantly dif-
ferent from the remaining subgroups and also associated
with worse outcome, as illustrated in Fig. 2a (p=0.003,
n=206). When indicating all four subgroups, the double
high subgroup separated significantly from the two
subgroups of low progranulin expression (p=0.021 and
p=0.005), whereas there was a non-significant trend for
a difference between the double high group and progra-
nulin high group with low sortilin expression (p=0.170)
(Fig. 2b). In order to clarify the significance of adding
sortilin expression to progranulin, we performed multi-
variable Cox Proportional Hazard (CPH) regression ana-
lyses, only analyzing patients with high progranulin
tumor expression. In support for an important additive
function for sortilin in the progranulin high patient
group, high tumor tissue expression of sortilin was sig-
nificantly linked to BCSS (HR=3.013, 95% CI: 1.219–
7.448, p=0.017) together with lymph node (LN) positivity
(HR=3.854, 95% CI: 1.666–8.919, p=0.002) and tumor
size (HR=1.089, 95% CI: 1.037–1.143, p=0.001) (C-index:
0.701) (see Additional file 5: Table S4).
The univariate analysis (Table 2), linking the double
high progranulin and sortilin to reduced BCSS in un-
treated patients, was further validated by multivariable
CPH regression analysis in the two subsets of patients
including progranulin and sortilin co-expression as well
as regular prognostic parameters available for the study.
Results showed that high progranulin and sortilin co-
expression, together with grade and LN status, were
Table 2 Cox regression analysis on randomized untreated patients. Univariate and multivariable interaction analysis on breast
cancer-specific survival evaluating various prognostic parameters for relative risk estimation for the untreated patient cohort.
Multivariable model adjusted for grade, lymph node status, tumor size, age, ERα and HER2 status, in addition to the progranulin/
sortilin scoring combination. HR: hazard ratio, CI: confidence interval, LN: lymph node, ERα: estrogen receptor alpha, HER2: human
epidermal growth factor receptor 2
Variable Univariate analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Grade
I-II 1 1
III 1.741 1.210–2.504 0.003 1.737 1.054–2.860 0.030
LN status
LN negative 1 1
LN positive 1.964 1.244–3.101 0.004 2.250 1.348–3.758 0.002
Tumor size
Continuous (mm) 1.014 0.997–1.032 0.108 1.020 0.999–1.041 0.059
Age
Continuous (per year) 0.966 0.936–0.997 0.033 0.968 0.934–1.003 0.077
ERα
ERα negative 1 1
ERα positive 0.824 0.525–1.294 0.401 1.259 0.678–2.340 0.466
HER2
HER2 negative 1 1
HER2 positive 1.376 0.849–2.230 0.195 1.152 0.648–2.046 0.629
Progranulin/sortilin combination
Mixed 1 1
Double high progranulin/sortilin 1.922 1.224–3.017 0.005 2.188 1.317–3.637 0.003
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identified as significant risk factors for BCSS (double
high: HR=2.188, 95% CI: 1.317–3.637, p=0.003, high
grade: HR=1.737, 95% CI: 1.054–2.860, p=0.030, LN
positivity; HR=2.250, 95% CI: 1.348–3.758, p=0.002, re-
spectively) (C-index: 0.667) (Table 2, right). Next, we in-
cluded all patients available within the randomized study
in order to increase the statistical power of the data. In
this extended patient material, including tamoxifen
treated patients, high co-expression of progranulin and
sortilin was significantly linked to BCSS (p=0.003, n=
395) as illustrated in Additional file 5: Fig. S3. In
addition, univariate and multivariable CPH analysis on
all patients revealed comparable results as for the un-
treated patients (C-index: 0.642) (see Additional file 5:
Table S5). Here, endocrine treatment with tamoxifen
was also identified as an independent prognostic variable
(HR=0.710, 95% CI: 0.517–0.974, p=0.034). Interestingly,
the double high group was not associated with any of
the established clinicopathological parameters, including
grade (p=0.063) and Ki67 (p=0.066) (see Additional file
5: Table S6).
High tumor co-expression of progranulin and sortilin was
not associated with tamoxifen resistance
Since the analyzed cohort include randomized untreated
and tamoxifen treated patients, we could define a poten-
tial tamoxifen response or resistance in the subgroup of
patients with high co-expression of progranulin and sor-
tilin. These analyses were restricted to patients with ERα
positive breast cancer, where high tumor co-expression
of progranulin and sortilin demonstrated a significantly
worse BCSS compared to mixed groups (p=0.005, n=
279) (Fig. 3a) similar to all samples described above. In
addition, we observed that the co-expression of progra-
nulin and sortilin has a significantly worse BCSS com-
pared to patients in the mixed group also in the ERα
positive breast cancer patients treated with tamoxifen
(p=0.034 n=126), representing the treatment status of
today’s ERα positive breast cancer patients (see Add-
itional file 5: Fig. S4).
Further, in the ERα positive subgroup, multivariable
analysis revealed that the double high group (HR=1.980,
95% CI: 1.308–2.996, p=0.001) as well as grade (HR=
1.612, 95% CI: 1.086–2.394, p=0.018) and HER2 positiv-
ity (HR=1.716, 95% CI: 1.027–2.867, p=0.039) were sig-
nificantly associated with reduced BCSS in ERα positive
breast cancer and that tamoxifen treatment significantly
improved ERα positive BCSS (HR=0.628, 95% CI: 0.431–
0.915, p=0.015) (C-index: 0.637) (see Additional file 5:
Table S7). When analyzing the response to tamoxifen
treatment, the ERα positive patients with double high
expression revealed no significant improvement in BCSS
comparing untreated patients with the tamoxifen treated
group (p=0.231, n=55) (Fig. 3b) in contrast to the
remaining group with mixed progranulin and sortilin ex-
pression (p=0.046, n=224) (Fig. 3c). This potential differ-
ence in tamoxifen response was nevertheless not
significant in an interaction analysis (p=0.971), suggest-
ing that despite the lack of significant response to tam-
oxifen treatment in the univariate analysis, the double
Fig. 2 Untreated patients with high tumor co-expression of progranulin and sortilin have worse breast cancer-specific survival. a Kaplan-Meier
curves illustrating breast cancer-specific survival on combined progranulin and sortilin expression, making a double high group (high progranulin,
high sortilin expression) against all other combinations (of low/high progranulin/sortilin expression) for the randomized untreated patients only
(n=206). b BCSS looking at all different progranulin/sortilin combinations in randomized untreated group only (n=206). The statistical differences
between the curves, as well as HR and 95% CI were estimated by the log-rank test. BCSS: breast cancer-specific survival, HR: hazard ratio, CI:
confidence interval, PGRN: progranulin, SORT: sortilin
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high group was not resistant to tamoxifen treatment.
Altogether, these results suggest that high co-expression
of progranulin and sortilin recognizes an ERα positive
patient group that could benefit from complementary
therapy, possibly targeting sortilin.
Discussion
Despite valuable traditional cancer therapies, many
breast cancer patients experience relapse and therapy re-
sistance. Thus, it is vital to continue to search for media-
tors driving tumor progression and identify biomarkers
that better predict high-risk patients having breast tu-
mors with more aggressive and potentially therapy-
resistant behavior. The interest in progranulin has
emerged over the last years, with publications demon-
strating an overexpression of progranulin in different
cancer types and associations with poor prognosis and
survival [9, 12, 13, 24–30]. Further, the progranulin re-
ceptor sortilin has been linked to breast cancer aggres-
siveness as well as being expressed in other types of
cancer, such as prostate and ovarian cancer [32, 40, 41].
Recent studies from our group have emphasized the
stem cell propagating effect by progranulin through its
receptor sortilin [7], indicating that this pathway could
be central in mediating CSC properties during tumor
progression. The existence of a targetable receptor fur-
ther suggest that future cancer therapies could be devel-
oped, selectively targeting CSC propagation via sortilin.
Here, we analyzed the expression levels of both pro-
granulin and its receptor sortilin in a large and unique
randomized clinical trial with long-term follow-up in
order to clarify if tumor co-expression defined any spe-
cific breast cancer type in relation to clinical aggressive-
ness. The results indeed revealed that high co-
expression of progranulin and sortilin could be detected
in 20% of the patients and was associated with decreased
BCSS. In support for an important function of progranu-
lin and sortilin activation in breast cancer progression,
multivariable regression analysis identified high co-
expression of progranulin and sortilin, as well as histo-
logical grade and lymph node status as independent risk
factors.
Previous reports have associated high progranulin ex-
pression with ERα negative patients [19] as well as a pre-
dictive marker for recurrence in ERα positive breast
cancer [14]. We recently showed that progranulin secre-
tion increased in ERα positive breast cancer when cells
were subjected to hypoxia, whereas ERα negative breast
cancer cells had constitutive high secretion of progranu-
lin [7]. Here we observed a significant link between pro-
granulin and HIF1α, where tumors with high expression
of HIF1α tend to express high progranulin. The positive
link of progranulin expression with HIF1α suggests a
hypoxic influence on progranulin expression, which is in
line with previous published data [7]. Further, we ob-
served that high progranulin expression tend to associate
with ERα negative status. In contrast, high sortilin ex-
pression was associated with ERα positive tumors, which
suggests that even though progranulin associated with
sortilin, their respective link to ERα are different. Al-
though, the clinical relevance of hypoxic driven progra-
nulin induced CSC propagation in different breast
cancer subtypes needs to be studied further.
Sortilin has previously been associated with breast can-
cer aggressiveness and contributes to tumor cell adhe-
sion and invasion [32]. We recently published that a
small molecule inhibitor of sortilin (AF38469) block pro-
granulin induced breast cancer progression in vivo [7,
42]. In this study, orally administration of AF38469 sig-
nificantly reduced the development of metastasis, which
Fig. 3 ERα positive patients with high progranulin and sortilin co-expression have worse breast cancer-specific survival. a-c Kaplan-Meier curves
illustrating breast cancer-specific survival in all ERα positive patients. a BCSS in the double high group (high progranulin, high sortilin expression)
against all other combinations (mixed group) in the ERα positive population (n=279). b-c Tamoxifen response shown by BCSS in all ERα positive
patients stratified by b double high group (n=55) or c mixed progranulin/sortilin expression (n=224). The statistical differences between the
curves, as well as HR and 95% CI were estimated by the log-rank test. BCSS: breast cancer-specific survival, HR: hazard ratio, CI: confidence
interval, PGRN: progranulin, SORT: sortilin
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suggest that sortilin may function as a therapeutic target
in breast cancer.
Here, in this cohort, high sortilin tumor expression on
its own demonstrated no significant reduction of BCSS in
either all patients or in the randomized control group (a
Kaplan-Meier plot of the sortilin expression is shown in
Additional file 6). However, the combination of high
tumor co-expression of progranulin and sortilin demon-
strated a significantly worse BCSS. Importantly, multivari-
able analysis revealed that when analyzing the progranulin
high subgroup separately, high sortilin expression was
identified as a significant prognostic variate linked to
worse BCSS together with lymph node positivity and
tumor size. This support the fact that sortilin adds prog-
nostic information when combined with progranulin.
Current treatment for patients with ERα positive tu-
mors includes endocrine therapy, such as tamoxifen.
Therefore, we additionally analyzed the prognostic value
of tumor co-expression of progranulin and sortilin in
ERα positive tumors subjected to tamoxifen treatment in
order to represent today’s population of luminal breast
cancer. Importantly, in this tamoxifen treated ERα posi-
tive patient group, the tumor co-expression of progranu-
lin and sortilin also showed a significantly worse BCSS.
Further, previous report described progranulin to be as-
sociated with resistance towards tamoxifen therapy [8].
Moreover, another report suggested that progranulin
levels predicted recurrence in patients with hormone re-
ceptor positive breast cancer during tamoxifen treatment
[13]. Here, multivariable interaction analysis identified
that the double progranulin/sortilin high ERα positive
group was not resistant to tamoxifen treatment, even
though univariate analysis demonstrated no significant
improvement in BCSS in the tamoxifen treated group.
Notably, limitations in this study includes that the tamoxi-
fen treatment in this cohort is restricted to premenopausal
women with only 2 years of adjuvant treatment and BCSS
may also have been affected by later therapies, which are
not considered in this cohort, at disease recurrence.
Conclusion
In conclusion, we have shown that a combination of
high progranulin and high sortilin tumor tissue expres-
sion defines a novel and highly malignant subgroup of
breast cancer patients. Whether these patients may
benefit from complementary targeted anti-sortilin based
therapies needs to be investigated.
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The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-07854-0.
Additional file 1:. REMARK guidelines. Checklist with REporting
recommendations for tumor MARKer prognostic studies
Additional file 2:. Progranulin antibody validation. Validation of the
progranulin antibody (AF2420, R&D Systems) using Western blotting and
immunohistochemistry. Weak or no staining was seen in MCF10a and
MDA-MB-468, while strong positive staining was seen in MDA-MB-231
and T47D (A). Correspondingly, protein extracts from MDA-MB-231 and
T47D gave an intense band at between 70 and 100 kDa using Western
blotting and protein extracts from MCF10a and MDA-MB-468 produced
very weak bands (B, left). Knockdown experiments using either Scr. Con-
trol or siGRN confirmed progranulin antibody specificity (B, right). Repre-
sentative images of three independent experiments. Scale bar represents
100 μm.
Additional file 3:. Sortilin antibody validation. Validation of the sortilin
antibody (ab16640, Abcam) using Western blotting and
immunohistochemistry. Weak or no staining was seen in MCF10a and
CAL-120, while strong positive staining was seen in T47D and MCF7 (A).
Correspondingly, protein extracts from T47D and MCF7 gave an intense
band at ~ 95 kDa using Western blotting and protein extracts from
MCF10a and CAL-120 produced only faint bands (B). Knockdown experi-
ments using either (C) Scr. Control or siSORT1, as well as (D) treating cells
with a sortilin degrader, MPEP (M; 1–1[2-(2-tert-butyl-5-methylphenoxy)-
ethyl-3-methylpiperidine; Lee, Almeida et al. 2014) confirmed sortilin anti-
body specificity in T47D. Representative images of three independent ex-
periments. Scale bar represents 100 μm.
Additional file 4: GRN and SORT1 gene expression in various cell lines.
(A) mRNA expression of progranulin (GRN) and sortilin (SORT1) were
analyzed by qPCR. Primers used were as follows: 5′-CCAAAGATCAGGTA
ACAACTCCG-3′ (forward strand) and 5’CATCGACCATAACACAGCACG − 3′
(reverse strand) for GRN and 5′-ATGGGAAGAAATCCACAAAGCAG − 3′
(forward strand) and 5′-ATTCCAGAGCCCCAAGGTCAG-3′ (reverse strand)
for SORT1 and 5′- GATGCGTGCCCAAGGAC − 3′ (forward strand) and 5′-
CAGGTCTAAATCGGGGTGG-3′ (reverse strand) for gene ribosomal protein
S26 (RPS26). The results were analyzed using GenEx Software (GenEx 7.0,
MultiD Analysis AB) and normalized to those of the housekeeping gene
RPS26 (reference gene). Result are shown as mean ±SEM from at least
three independent experiments. Statistical significance was calculated
using one-way ANOVA adjusted for multiple comparison, where *P< 0.05,
**P< 0.01 and ***P< 0.001. (B) Transcriptional profiling performed by Neve
and colleagues that the gene expression of GRN and SORT1 is similar to
what we have detected at both mRNA and protein level for the relevant
cell lines. Data modified from (Neve RM et al. Cancer Cell. 2006).
Additional file 5: Supplementary material. Fig. S1: CONSORT
diagram for the study. Flowchart of the study showing the enrollment of
the patients, treatment allocation and analysis. Fig. S2: ERα positive
patients stratified by treatment arm. Kaplan-Meier estimates showing
breast cancer-specific survival in ERα positive breast cancer patients
treated with tamoxifen or randomized untreated. Fig. S3: Patients with
high tumor co-expression of progranulin and sortilin have worse breast
cancer-specific survival. Kaplan-Meier curves illustrating breast cancer-
specific survival on combined progranulin and sortilin expression, show-
ing high expression of both markers against all other combinations for all
patients. Fig. S4: Patients with high tumor co-expression of progranulin
and sortilin have worse breast cancer-specific survival in the ERα positive
patient group treated with tamoxifen. Kaplan-Meier estimates showing
breast cancer-specific survival on combined progranulin and sortilin ex-
pression, showing high expression of both markers against all other com-
binations in ERα positive breast cancer patients treated with tamoxifen.
Table S1: Distribution of progranulin scores according to clinicopatho-
logical parameters in the cohort. Statistics on progranulin scoring in rela-
tion to clinical parameters. Table S2: Distribution of sortilin expression
according to clinicopathological parameters in the cohort. Statistics on
sortilin scoring in relation to clinical parameters. Table S3: Cross table.
The relationship between progranulin and sortilin expression in the pa-
tient cohort. Table S4: Cox regression analysis on randomized untreated
patients with high progranulin tumor tissue expression. Multivariable
interaction analysis on breast cancer-specific survival evaluating various
prognostic parameters for relative risk estimation for the untreated pa-
tient cohort having high tumor expression of progranulin. Table S5: Cox
regression analysis on all patients. Univariate and multivariable interaction
analysis on breast cancer-specific survival evaluating various prognostic
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parameters for relative risk estimation for all patients in the cohort. Table
S6: Distribution of co-expression of progranulin and sortilin according to
clinicopathological parameters in the cohort. Statistics on co-expression
of progranulin and sortilin scoring in relation to clinical parameters. Table
S7: Cox regression analysis on ERα positive patients. Multivariable regres-
sion analysis on breast cancer-specific survival evaluating various prog-
nostic parameters for relative risk estimation for the ERα positive patient
cohort.
Additional file 6. Sortilin tumor expression on its own shows no
difference in survival. Kaplan-Meier curves illustrating breast cancer-
specific survival according to high or low sortilin expression.
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